1. From the Departments of Neurology (D.L.T., W.T.L., K.J.B.) and Epidemiology (W.T.L.), Harborview Medical Center, University of Washington School of Medicine, Seattle; MSM INCARA Pharmaceutical Corp and Aeolus Pharmaceuticals, Inc (R.E.G.), Research Triangle Park, NC; Interneuron Pharmaceuticals, Inc (L.A.S.), Lexington, Mass; the Department of Neurology (S.H.), Stanford University School of Medicine, Stanford, Calif; and the Department of Neurology (L.B.M.), University of Michigan, Ann Arbor.